Positions

Overview

  • Dr. Solomon's clinical interest centers on the care of CF and non-CF bronchiectasis patients and the pursuit of continued inpatient medicine care of these patients in the acute care setting.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation.  Journal of Cystic Fibrosis.  20:e69-e71. 2021
    2021 avorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic.  Annals of the American Thoracic Society.  18:1588-1592. 2021
    2021 Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.  Journal of Cystic Fibrosis.  20:399-401. 2021
    2021 PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.  Journal of Cystic Fibrosis.  20:205-212. 2021
    2021 Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.  Journal of Cystic Fibrosis.  2021
    2020 CFTR targeted therapies: Recent advances in cystic fibrosis and possibilities in other diseases of the airways.  European Respiratory Review.  29:1-13. 2020
    2019 Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.  International Forum of Allergy and Rhinology.  9:1430-1435. 2019
    2019 Area deprivation as a risk factor for methicillin-resistant Staphylococcus aureus infection in pediatric cystic fibrosis 2019
    2019 Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging.  Biomedical Optics Express.  10:5414-5430. 2019
    2019 Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.  Journal of Cystic Fibrosis.  18:579-580. 2019
    2019 Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.  Science Translational Medicine.  11. 2019
    2019 Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.  Journal of Cystic Fibrosis.  18:536-542. 2019
    2019 Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis.  BMC Pulmonary Medicine.  19. 2019
    2019 Colocolonic intussusception in an adult cystic fibrosis patient.  Journal of Cystic Fibrosis.  18:e11-e13. 2019
    2019 The economic burden of bronchiectasis - Known and unknown: A systematic review.  BMC Pulmonary Medicine.  19. 2019
    2019 Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: A cross-sectional study.  Annals of the American Thoracic Society.  16:150-153. 2019
    2019 CFTR modulator theratyping: Current status, gaps and future directions.  Journal of Cystic Fibrosis.  18:22-34. 2019
    2019 Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.  Journal of Cystic Fibrosis.  18:102-109. 2019
    2019 Proline-glycine-proline peptides are critical in the development of smoke-induced emphysema.  American Journal of Respiratory Cell and Molecular Biology.  61:560-566. 2019
    2018 Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice.  Nature Communications.  9. 2018
    2018 Standardized measurement of nasal membrane transepithelial potential difference (NPD).  Journal of Visualized Experiments.  2018. 2018
    2018 Seeing cilia: Imaging modalities for ciliary motion and clinical connections 2018
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia.  American Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2018 Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.  BMC Pulmonary Medicine.  18. 2018
    2017 A multiple reader scoring system for Nasal Potential Difference parameters.  Journal of Cystic Fibrosis.  16:573-578. 2017
    2017 Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.  Journal of Cystic Fibrosis.  16:592-599. 2017
    2017 Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.  Journal of Cystic Fibrosis.  16:600-606. 2017
    2017 The therapeutic potential of CFTR modulators for COPD and other airway diseases.  Current Opinion in Pharmacology.  34:132-139. 2017
    2017 Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites.  American Journal of Human Genetics.  100:751-765. 2017
    2017 Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.  Journal of Cystic Fibrosis.  16:371-379. 2017
    2017 Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography..  JCI insight.  2:e91702. 2017
    2017 Flexible, high-resolution micro-optical coherence tomography endobronchial probe toward in vivo imaging of cilia.  Optics Letters.  42:867-870. 2017
    2017 Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.  Journal of Cystic Fibrosis.  16:24-29. 2017
    2016 Airway progenitor clone formation is enhanced by Y-27632-dependent changes in the transcriptome.  American Journal of Respiratory Cell and Molecular Biology.  55:323-336. 2016
    2016 Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.  Cell Stem Cell.  19:217-231. 2016
    2016 In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.  Biomedical Optics Express.  7:2494-2505. 2016
    2016 Pilot evaluation of ivacaftor for chronic bronchitis 2016
    2016 Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy 2016
    2016 Neutrophil fates in bronchiectasis and alpha-1 antitrypsin deficiency.  Annals of the American Thoracic Society.  13:S123-S129. 2016
    2016 Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in Chronic bronchitis.  Annals of the American Thoracic Society.  13:S169-S176. 2016
    2016 Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.  Clinics in Chest Medicine.  37:147-158. 2016
    2015 Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.  Pediatric Pulmonology.  50:S3-S13. 2015
    2015 Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.  Chest.  147:e79-e82. 2015
    2015 Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.  Journal of Cystic Fibrosis.  14:228-236. 2015
    2013 IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations.  PLoS ONE.  8. 2013
    2013 Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.  Journal of Surgical Research.  183:767-776. 2013
    2013 Mycobacterium abscessus Induces a Limited Pattern of Neutrophil Activation That Promotes Pathogen Survival.  PLoS ONE.  8. 2013
    2013 Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.  Chest.  144:200-207. 2013
    2010 An international randomized multicenter comparison of nasal potential difference techniques.  Chest.  138:919-928. 2010
    2008 Potential role of high-mobility group box 1 in cystic fibrosis airway disease.  American Journal of Respiratory and Critical Care Medicine.  178:822-831. 2008
    2006 Airborne mold and endotoxin concentrations in New Orleans, Louisiana, after flooding, October through November 2005.  Environmental Health Perspectives.  114:1381-1386. 2006

    Research Overview

  • Dr. Solomon's research goal is the pursuit of translational sciences and an academic medical career focusing on the use of in vivo and in vitro ion transport, inflammatory, and rheological research techniques to explore mechanisms of disease and opportunities for novel treatments in CF, non-CF bronchiectasis patients and the pursuit of continued inpatient medicine care of these patients in the acute care setting.

    • Principal Investigator On

  • A CF 3N Model of the Future: Proposal for Piloting a Learning Health System  awarded by CINCINNATI CHILDREN'S HOSPITAL
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study) (PROMISE-OB-18)  awarded by Cystic Fibrosis Foundation ^
  • Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis (aka CASE.4.CF)  awarded by UNIVERSITY OF WASHINGTON
  • Award for a Physical Therapist  awarded by Cystic Fibrosis Foundation ^
  • Cystic Fibrosis Learning Network: A CF C3N Model of the Future: Proposal for Piloting a Learning Health System  awarded by CINCINNATI CHILDREN'S HOSPITAL
  • Cystic Fibrosis Lung Transplant Transition LLC2  awarded by Cystic Fibrosis Foundation ^
  • Development of the CF Stress Questionnaire: Testing and Validation  awarded by BOSTON CHILDREN'S HOSPITAL
  • Evaluation of Predictors of Maternal-Fetal Outcomes in Cystic Fibrosis  awarded by University of Texas Southwestern Medical Center at Dallas
  • Functional Categorization of Ciliary Motion in PCD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Implementation Of The Depression And Anxiety Guidelines Award For A Mental Health Coordinator  awarded by Cystic Fibrosis Foundation ^
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Potential Difference Measures Core for Advancing CFTR Therapeutics  awarded by Cystic Fibrosis Foundation ^
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROQR THERAPEUTICS
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by PARION SCIENCES, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELECTROMED, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELECTROMED, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Rare Cell Collection Protocol for CF Patients with Rare CFTR Mutations (RACE)  awarded by CYSTIC FIBROSIS FOUNDATION THERAPEUTICS., INC
  • Rare Mutations in Cystic Fibrosis: Overcoming Barriers to Personalized Medicine  awarded by Emory University
  • Standardized Treatment of Pulmonary Exacerbations II  awarded by SEATTLE CHILDREN'S HOSPITAL
  • UAB Cystic Fibrosis Center For Care Teaching And Research (Adult)  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Therapeutic Development Network Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^

    • Investigator On

  • A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • A Multi-site Trial of Specialist Palliative Care in CF  awarded by Emory University
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)  awarded by Cystic Fibrosis Foundation ^
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")  awarded by SEATTLE CHILDREN'S HOSPITAL
  • An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis  awarded by University of Pennsylvania
  • Award for a Physical Therapist  awarded by Cystic Fibrosis Foundation ^
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Implementation of Direct-to-Patient Telemedicine Healthcare Initiatives  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Nasal Epithelial Cells as an Outcome Tool for Individualized CFTR Therapies  awarded by Cystic Fibrosis Foundation ^
  • Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations  awarded by EMILY'S ENTOURAGE
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by PROGENRA, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CELTAXSYS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC.
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Research Development Program  awarded by Cystic Fibrosis Foundation ^
  • Therapeutic Development Center - UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation ^
  • Translational Program in CFTR-Related Airway Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core A  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C: Clinical & Translational Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB Research Development Program Component II - Overall Program  awarded by Cystic Fibrosis Foundation ^
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^

    • Education And Training

  • UAB Hospital, Residency
  • University of Colorado Health Sciences Center, Postdoctoral Fellowship
  • Doctor of Medicine, University of Alabama at Birmingham 2007

    • Full Name

  • George Solomon